Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinical Hospital, shared a post on LinkedIn:
“Great to be in Cork, Ireland, for the Annual Meeting of the Definitive Consortium.
The Definitive Trial project is a Horizon EU European Commission–funded clinical trial aiming to show that personalized treatment decisions in early-stage HER2-positive breast cancer, guided by the HER2DX diagnostic assay, can improve quality of life without compromising outcomes or survival.
The consortium brings together 18 partners across 7 countries, combining clinical, translational, and methodological expertise to address this question at a truly European scale. Importantly, the trial is now approved and actively running across all participating countries.
Beyond clinical outcomes, DEFINITIVE also aims to demonstrate that HER2DX is safe, efficient, and capable of reducing direct and indirect costs for hospitals and public health systems.
A special thanks to Roisin Connolly and her team at University College Cork for the excellent hosting.”
More posts featuring Aleix Prat on OncoDaily.
